Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2024-04-01 00:00:00 ET · period of report 2024-03-28 · accession 0000950170-24-039319 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-04-01 | 2024-03-28 | BEAM | Evans John M. | CEO, Dir | S - Sale | $33.86 | -60.0K | 998.3K | -6% | -$2.03M |
| T | 2024-04-01 | 2024-03-31 | BEAM | Evans John M. | CEO, Dir | A - Grant | $0.00 | +77.5K | 1.08M | +8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-28 | S | D | 60,000 | $33.86 | 998,262 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.374 to $34.15, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2024-03-31 | A | A | 77,500 | $0.00 | 1,076,445 | D | — | — | (F3) Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. (F4) Includes 683 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2024. |